Response Oncology, Inc.
Not enough financial coverage to compute a composite score for ROIX. This is typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available data still render below.
Company
Response Oncology, Inc. does not have significant operations. The company, along its wholly owned and majority owned subsidiaries, operated as a comprehensive cancer management company.
- CEO
- Charles E. Sweet
- IPO
- 2000
- Employees
- 10
- HQ
- US
Price Chart
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -19.14
- Avg Volume
- 68.00K
Get TickerSpark's AI analysis on ROIX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ROIX Coverage
We haven't published any research on ROIX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ROIX Report →